



## Cinqair® (reslizumab) (Intravenous)

Document Number: CGHC-273

Last Review Date: 10/01/2021

Date of Origin: 05/31/2016

Dates Reviewed: 05/2016, 06/2017, 09/2017, 12/2017, 03/2018, 06/2018, 10/2018, 10/2019, 10/2020, 10/2021

### I. Length of Authorization

Initial authorization is valid for six months and is eligible for renewal.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC unit]:

- 100 mg single-use vial: 4 vials every 28 days

#### B. Max Units (per dose and over time) [HCPCS Unit]:

- 345 billable units every 4 weeks

### III. Initial Approval Criteria <sup>1</sup>

Coverage is provided in the following conditions:

- Fasenra and Nucala are the preferred drugs . Patient must have failed, or have a contraindication, or intolerance to Fasenra or Nucala prior to consideration of Cinqair; **AND**
- Patient is at least 18 years of age; **AND**

#### Universal Criteria <sup>1</sup>

- Will not be used in combination with other anti-IgE, anti-IL4, or anti-IL5 monoclonal antibody (e.g., omalizumab, mepolizumab, benralizumab, dupilumab, etc.); **AND**
- Must NOT be used for either of the following:
  - Treatment of other eosinophilic conditions (e.g., allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome, etc.)
  - Relief of acute bronchospasm or status asthmaticus; **AND**

#### Severe Asthma † <sup>1,2,3,5,6</sup>

- Patient must have severe\* disease; **AND**

- Patient must have asthma with an eosinophilic phenotype indicated by blood eosinophils  $\geq$  400 cells/ $\mu$ L within 4 weeks of dosing; **AND**
- Must be used for add-on maintenance treatment in patients regularly receiving BOTH of the following:
  - Medium to high-dose inhaled corticosteroids; **AND**
  - An additional controller medication (e.g., long acting beta agonist, leukotriene modifiers, etc.); **AND**
- Patient must have two or more exacerbations in the previous year requiring daily oral corticosteroids for at least 3 days (in addition to the regular maintenance therapy defined above); **AND**
- Baseline measurement of at least one of the following for assessment of clinical status:
  - Use of systemic corticosteroids
  - Use of inhaled corticosteroids
  - Number of hospitalizations, ER visits, or unscheduled visits to healthcare provider due to condition
  - Forced expiratory volume in 1 second (FEV<sub>1</sub>)

**\*Components of severity for classifying asthma as severe may include any of the following (not all inclusive):**

- Symptoms throughout the day
- Nighttime awakenings, often 7x/week
- SABA use for symptom control occurs several times per day
- Extremely limited normal activities
- Lung function (percent predicted FEV<sub>1</sub>) <60%
- Exacerbations requiring oral systemic corticosteroids are generally more frequent and intense relative to moderate asthma

† FDA approved Indication(s)

#### IV. Renewal Criteria <sup>1,5,6</sup>

- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: malignancy, parasitic (helminth) infection, and anaphylaxis, etc.; **AND**
- Treatment has resulted in clinical benefit:
  - Improvement in asthma symptoms or asthma exacerbations as evidenced by decrease in one or more of the following:
    - Use of systemic corticosteroids
    - Two-fold or greater decrease in inhaled corticosteroid use for at least 3 days
    - Hospitalizations
    - ER visits
    - Unscheduled visits to healthcare provider; **OR**
  - Improvement from baseline in forced expiratory volume in 1 second (FEV<sub>1</sub>)

## V. Dosage/Administration<sup>1</sup>

Indication	Dose
Severe Asthma with an eosinophilic phenotype	3 mg/kg via intravenous infusion every 4 weeks

## VI. Billing Code/Availability Information

### HCPCS code:

- J2786 - Injection, reslizumab, 1 mg: 1 billable unit = 1 mg

### NDC:

- 100 mg/10 mL single-use vial: 59310-0610-xx

## VII. References

1. Cinqair [package insert]. West Chester, PA; Teva Respiratory, LLC; February 2020. Accessed August 2021.
2. National Asthma Education and Prevention Program (NAEPP). Guidelines for the diagnosis and management of asthma. Expert Panel Report 3. Bethesda, MD: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI); August 2007.
3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2020 Update. Available from: <http://www.ginasthma.org>. Accessed September 2020.
4. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med* 2015;3:355-66.
5. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS Guidelines on Definition, Evaluation, and Treatment of Severe Asthma. *Eur Respir J* 2014; 43: 343-373.
6. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J* 2020; 55: 1900588 [<https://doi.org/10.1183/13993003.00588-2019>].
7. National Asthma Education and Prevention Program (NAEPP). 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Bethesda, MD: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI); December 2020.
8. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2021 Update. Available from: <http://www.ginasthma.org>. Accessed August 2021.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
J45.50	Severe persistent asthma, uncomplicated

ICD-10	ICD-10 Description
J82.81	Eosinophilic pneumonia, NOS
J82.82	Acute eosinophilic pneumonia
J82.83	Eosinophilic asthma
J82.89	Other pulmonary eosinophilia, not elsewhere classified

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC